palmitoylethanolamide.com.au
HomeResearchBentivenga 2025

Retrospective Evaluation of L-Acetyl Carnitine and Palmitoylethanolamide as Add-On Therapy in Patients with Fibromyalgia and Small Fiber Neuropathy

Bentivenga C, Cicero AFG, Fogacci F, Politi NE, Di Micoli A, Cosentino ER, Gionchetti P, Borghi C. Pharmaceutics, 2025; 17(8):1004.

Observational studyHumansWith acetyl-L-carnitine, Boswellia serrata and vitamins B6 and E

This study tested palmitoylethanolamide together with acetyl-L-carnitine, Boswellia serrata and vitamins B6 and E. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design
Observational study
Subjects
86 patients with fibromyalgia after matching, 43 in each group
Dose used in the study
600 mg of palmitoylethanolamide with 500 mg of acetyl-L-carnitine twice a day for 8 weeks, then once a day (Kalanit), added to standard care
Duration
12 weeks
What was measured
The revised Fibromyalgia Impact Questionnaire

What the authors reported

A median fall of 19 points on the questionnaire in the add-on group (p < 0.001), versus 1 point in the standard care group (p = 0.12).

Limits of this study

A retrospective study of patient records, which the authors note is prone to selection bias. The product contains several active compounds, and the authors state that this prevents assigning the result to any one of them. The outcome was self-reported. The study received no external funding.

Source

doi:10.3390/pharmaceutics17081004

Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.